10
~~37~~. (Amended) Nitrogen heterocyclic aromatic derivative having the following structure:



(XVII)

12 ~~39~~. (Amended) The pharmaceutical composition comprising a nitrogen heterocyclic aromatic derivative according to claim 10 ~~37~~ in the form of a transdermal skin patch.

13
~~40~~. (Amended) The pharmaceutical composition comprising a nitrogen heterocyclic aromatic derivative according to claim 10 ~~37~~ for intravenous administration.

Cancel claims 47 and 48 and add the following new claims:

20 ~~49~~. (New) A method of reducing the humoral and cellular immunological response of a mammal comprising administering an effective amount of a nitrogen heterocyclic aromatic derivative having the following general formula:



(I)

where X and Y are selected from N, C and CH, provided they are different from each other, or X and Y are both nitrogen;

R is hydrogen or -COR_8 where R_8 is a saturated or non-saturated C_1-C_{10} aliphatic hydrocarbon, R_1 has the following general formula:



(II)

where R_3 is hydrogen, halogen, C_1-C_{10} alkyl or C_1-C_{10} alkoxyl, R_4 is hydrogen, C_1-C_{10} alkyl or C_1-C_{10} alkoxyl, or R_3 and R_4 together form a methylendioxy group;

R_2 has the following general structure:



(III)

and R_5 is selected from:



where Z=OR_7 where R_7 is a saturated or non-saturated, linear or branched C_1-C_{10} aliphatic hydrocarbon, or R_7 has the following formula:



(XII)

where R, R_1, X and Y are defined as above and R_6 is hydrogen, halogen, alkyl or alkoxyl C_1-C_{10}, or Z is NHR_8 where R_8 is a linear or branched C_1-C_{20} alkyl chain,

provided that when X=Y=N and R is H or -$CONHCH_2CH_3$, Z is not NHR_8 where R_8 is -CH_2CH_3, and provided that R_1 and R_2 are not located on two adjacent atoms of the heterocyclic aromatic ring, and further provided that when X=Y=N and R_5 is -COZ where Z=OR_7, R_7 is a saturated or non-saturated linear or branched C_5-C_{20} aliphatic hydrocarbon.

~~30.~~ 21 (Amended) A method of treating a tumor susceptible to therapy comprising administering an effective amount of a nitrogen heterocyclic aromatic derivative having the following general formula:



(I)

where X and Y are selected from N, C and CH, provided they are different from each other, or X and Y are both nitrogen;

R is hydrogen or -COR_8 where R_8 is a saturated or non-saturated C_1-C_{10} aliphatic hydrocarbon, R_1 has the following general formula:



(II)

where R_3 is hydrogen, halogen, C_1-C_{10} alkyl or C_1-C_{10} alkoxyl, R_4 is hydrogen, C_1-C_{10} alkyl or C_1-C_{10} alkoxyl, or R_3 and R_4 together form a methylendioxy group;

R_2 has the following general structure:



(III)

and R_5 is selected from:



where Z=OR_7 where R_7 is a saturated or non-saturated, linear or branched C_1-C_{10} aliphatic hydrocarbon, or R_7 has the following formula:



(XII)

where R, R_1, X and Y are defined as above and R_6 is hydrogen, halogen, alkyl or alkoxyl C_1-C_{10}, or Z is NHR_8 where R_8 is a linear or branched C_1-C_{20} alkyl chain,

provided that when X=Y=N and R is H or $-CONHCH_2CH_3$, Z is not NHR_8 where R_8 is $-CH_2CH_3$, and provided that R_1 and R_2 are not located on two adjacent atoms of the heterocyclic aromatic ring, and further provided that when X=Y=N and R_5 is -COZ where $Z=OR_7$, R_7 is a saturated or non-saturated linear or branched C_5-C_{20} aliphatic hydrocarbon.

51. (New) A pharmaceutical composition comprising a nitrogen heterocyclic aromatic derivative according to claim 37 together with a pharmaceutically acceptable carrier or diluent.